ArticleeLife2018
The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 80 citations in OpenAlex.
- scDifformer: diffusion-based post-training for virtual cell modeling across large-scale single-cell data.Nucleic acids research · 2026Article
- Cross-reactive antibody and T-cell responses after influenza virus infection in community-dwelling older adults.Journal of virology · 2026Article
- scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Cytomegalovirus Drives the Development of Cytotoxic CD4Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Contextualizing TNature reviews. Immunology · 2026Review
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- A distinct subset of stem-cell memory is poised for the cytotoxicity program in CD4Science advances · 2026Article
- Cytotoxic CD4+ T cells in cancer: an emerging target for next-generation anticancer immunotherapy?Journal for immunotherapy of cancer · 2025Review
- Stem-like T cells: molecular regulation, functional diversity, and therapeutic implications across diseases.Journal of translational medicine · 2025Review
- Inferring cell-type-specific gene regulatory network from cellular transcriptomics data with GeneLink.Briefings in bioinformatics · 2025Article
- The Whole Blood Transcriptomic Analysis in Sickle Cell Disease Reveals RUNX3 as a Potential Marker for Vaso-Occlusive Crises.International journal of molecular sciences · 2025Article
- Single cell-resolved cellular, transcriptional, and epigenetic changes in mouse T cell populations linked to age-associated immune decline.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue.Biomedicines · 2025Article
- Co-expression of B7-H3 and LAG3 represents cytotoxicity of CD4Frontiers in immunology · 2025Article
- Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4Frontiers in immunology · 2025Article
- CD4Trends in cancer · 2024Review
- Bhlhe40 Promotes CD4+ T Helper 1 Cell and Suppresses T Follicular Helper Cell Differentiation during Viral Infection.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Cytotoxic CD4Med (New York, N.Y.) · 2023Article
- Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15.Cell reports · 2023Article
- Biophysical and mechanobiological considerations for T-cell-based immunotherapy.Trends in pharmacological sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 4 countries.
Yasmina Serroukh *Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.ORCID http://orcid.org/0000-0001-8751-5725
Chunyan Gu-Trantien *Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.
Baharak Hooshiar Kashani *Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.
Matthieu DefranceLaboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Bruxelles, Belgium.
Thien-Phong Vu ManhCentre d'Immunologie de Marseille-Luminy 13288, Aix Marseille Université UM2, Marseille, France.ORCID http://orcid.org/0000-0002-0294-342X
Abdulkader AzouzInstitute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.
Aurélie DetavernierInstitute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.
Alice HoyoisInstitute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.
Jishnu DasRagon Institute of MGH, MIT and Harvard University, Cambridge, United States.ORCID http://orcid.org/0000-0002-5747-064X
Martin BizetLaboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Bruxelles, Belgium.
Emeline PolletCentre d'Immunologie de Marseille-Luminy 13288, Aix Marseille Université UM2, Marseille, France.
Tressy TabbusoInstitute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.
Emilie CalonneLaboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Bruxelles, Belgium.
Klaas van GisbergenDepartment of Haematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands.
Marc DalodCentre d'Immunologie de Marseille-Luminy 13288, Aix Marseille Université UM2, Marseille, France.
François FuksLaboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Bruxelles, Belgium.
Stanislas GorielyInstitute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.ORCID http://orcid.org/0000-0002-7005-6195
Arnaud MarchantInstitute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium.ORCID http://orcid.org/0000-0003-0578-0467
Université Libre de Bruxelles · BEAix-Marseille Université · FRRagon Institute of MGH, MIT and Harvard · USSanquin · NL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic CD4 (CD4
Indexed as
Cell DifferentiationAdultAnimalsCells, CulturedCore Binding Factor Alpha 3 SubunitCytomegalovirus InfectionsDNA-Binding ProteinsFemaleGene Expression RegulationHumansMaleMiceMiddle AgedTh1 CellsT-Lymphocytes, CytotoxicT-Lymphocyte SubsetsCore Binding Factor Alpha 3 SubunitDNA-Binding ProteinsRunx3 protein, humanTranscription FactorsZBTB7B protein, humancytomegaloviruscytotoxic CD4 T cellhumanimmunologyinflammationRunx3T-betTh1 differentiationThPOK
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.